ライフサイエンスコーパス: adenomatous polyposis coli

1 ducin repeat-containing protein 2), and APC (adenomatous polyposis coli).

2 ng glycogen synthase kinase 3beta, axin, and adenomatous polyposis coli.

3 genic mechanism associated with mutations in Adenomatous Polyposis Coli.

4 urden in a murine tumor model of spontaneous adenomatous polyposis coli.

5 In addition we identified adenomatous polyposis coli 1 (APC1) as an interaction pa

6 Germline specific overexpression of Adenomatous Polyposis Coli 2 (APC2) rescued GSC loss in

7 sly in germ cells for proper localization of Adenomatous polyposis coli 2 and E-cadherin at the hub-G

8 ation of the centrosomal proteins Ninein and adenomatous polyposis coli abolished this bias.

9 tive regulators of beta-catenin, such as the adenomatous polyposis coli and Axin tumor suppressor pro

10 G-protein signaling (RGS) domain that binds adenomatous polyposis coli and Galpha subunits, thereby

11 that are typically associated with a loss of adenomatous polyposis coli and up-regulation of beta-cat

12 member 1, insulin-like growth factor 2, and adenomatous polyposis coli) and other solid tumors (e.g.

13 of the postsynaptic density, among them the adenomatous polyposis coli, and 2) proteins with express

14 aditionally attributed to mutations in Axin, adenomatous polyposis coli, and beta-catenin that lead t

15 generally lacked differentiation markers and adenomatous polyposis coli antigen.

16 e conditionally expressed a mutant allele of adenomatous polyposis coli (APC(cKO)) in murine uterine

17 n on chronic hypoxia-induced PH, we used the adenomatous polyposis coli (Apc(Min/+)) mouse, where red

18 ve shown that a cancer causing truncation in adenomatous polyposis coli (APC) (APC(1-1450)) dominantl

19 The tumor suppressor Adenomatous polyposis coli (APC) affects the function of

20 induced by the rare inheritance of a mutant adenomatous polyposis coli (Apc) allele.

21 ministering LPA to mice heterozygous for the adenomatous polyposis coli (Apc) allele.

22 contribution of the Wnt-regulating proteins adenomatous polyposis coli (APC) and APC2 in the pathoge

23 ested that specific GSK3 substrates, such as adenomatous polyposis coli (APC) and collapsin response

24 we show that two tumor suppressor proteins, adenomatous polyposis coli (APC) and Dlg1-SAP97, are req

25 wo microtubule plus end-associated proteins, adenomatous polyposis coli (APC) and EB1, providing a po

26 onal and transcriptional mechanisms and that adenomatous polyposis coli (APC) and GSK3beta, which are

27 expression of the gut tumor suppressor gene adenomatous polyposis coli (Apc) and its role in the oli

28 e, we report that mPar3 forms a complex with adenomatous polyposis coli (APC) and kinesin superfamily

29 Finally, CBC stem cells deficient in adenomatous polyposis coli (Apc) and Math1 were able to

30 associate with the tumor suppressor protein adenomatous polyposis coli (APC) and p150glued, a compon

31 ed by the colorectal cancer tumor suppressor adenomatous polyposis coli (APC) and that KLF4 repressed

32 ther, we find that both the tumor suppressor adenomatous polyposis coli (APC) and the ADP-ribose poly

33 nce microscopy to image the tumor suppressor adenomatous polyposis coli (APC) and the formin mDia1 du

34 firmed an expected loss in the expression of adenomatous polyposis coli (APC) and the transcriptional

35 First, patients with germline mutations in adenomatous polyposis coli (APC) are susceptible to stom

36 polyposis (FAP) but further study identified adenomatous polyposis coli (APC) as responsible for FAP

37 The adenomatous polyposis coli (APC) binding site of axin in

38 Here we find that the tumor suppressor adenomatous polyposis coli (APC) controls microtubule ta

39 associates with and blocks activation of the adenomatous polyposis coli (APC) destruction complex tha

40 C57BL/6J mice carrying the Min allele of Adenomatous polyposis coli (Apc) develop numerous adenom

41 Mutations in adenomatous polyposis coli (APC) disrupt regulation of W

42 rectal cancers consistently contained mutant adenomatous polyposis coli (APC) DNA molecules in their

43 show here that the tumor-suppressor protein adenomatous polyposis coli (APC) functions in localizing

44 As Adenomatous Polyposis Coli (APC) functions in many of th

45 mice bearing a heterozygote mutation in the adenomatous polyposis coli (APC) gene (Apc(Min/+) mice).

46 ted gene-targeted pigs with mutations in the adenomatous polyposis coli (APC) gene (APC) that are ort

47 The adenomatous polyposis coli (Apc) gene also plays an impo

48 of these models involve modification of the adenomatous polyposis coli (Apc) gene and are excellent

49 lasia) mice carry a dominant mutation in the adenomatous polyposis coli (Apc) gene and develop multip

50 hrough somatic second hit alterations of the adenomatous polyposis coli (APC) gene and frequently dem

51 ased in human cells with deficiencies in the adenomatous polyposis coli (APC) gene and in cells stimu

52 Mutations in the adenomatous polyposis coli (APC) gene and K-ras occur in

53 We show that a deficiency in the adenomatous polyposis coli (APC) gene and subsequent act

54 Mutations in the adenomatous polyposis coli (APC) gene are associated wit

55 Patients with mutations in the Adenomatous Polyposis Coli (APC) gene are at increased r

56 Somatic mutations of the adenomatous polyposis coli (APC) gene are initiating eve

57 Mutations in the adenomatous polyposis coli (APC) gene are pivotal in col

58 Genetic mutations in the adenomatous polyposis coli (APC) gene are thought to cau

59 Mutations in the human adenomatous polyposis coli (APC) gene are thought to ini

60 l cancer cell lines bearing mutations on the adenomatous polyposis coli (APC) gene as a model of FAP-

61 The adenomatous polyposis coli (APC) gene encodes APC tumour

62 using a Cre-LoxP strategy to inactivate the Adenomatous Polyposis Coli (Apc) gene in the murine rena

63 Since the Adenomatous Polyposis Coli (APC) gene is mutated in the

64 The Adenomatous Polyposis Coli (APC) gene is mutated in the

65 Although beta-catenin and adenomatous polyposis coli (APC) gene mutations are well

66 Adenomatous polyposis coli (APC) gene mutations have bee

67 Mutations in the adenomatous polyposis coli (APC) gene occur in the vast

68 ost colorectal cancers have mutations of the adenomatous polyposis coli (APC) gene or the beta-cateni

69 The adenomatous polyposis coli (APC) gene product is mutated

70 -, and gamma (gamma)-catenin, p120, p27, and adenomatous polyposis coli (APC) gene product.

71 letion in mice with inactivating mutation of adenomatous polyposis coli (APC) gene reduces intestinal

72 Mutations in the adenomatous polyposis coli (APC) gene result in uncontro

73 in-terminating mutation in one allele of the adenomatous polyposis coli (Apc) gene that is similar to

74 rase beta and in vivo point mutations of the adenomatous polyposis coli (APC) gene that leads to colo

75 ssf1a can cooperate with inactivation of the adenomatous polyposis coli (Apc) gene to accelerate inte

76 ization of beta-catenin or defective for the adenomatous polyposis coli (APC) gene to reinvestigated

77 Mutations in the Adenomatous Polyposis Coli (APC) gene up-regulate Wnt si

78 n the bladder as conditional deletion of the adenomatous polyposis coli (Apc) gene within the adult b

79 The adenomatous polyposis coli (APC) gene, a member of the W

80 Mutations in the adenomatous polyposis coli (APC) gene, which initiate al

81 intestinal carcinogenesis is mutation of the adenomatous polyposis coli (APC) gene, which leads to ac

82 requently bear inactivating mutations of the adenomatous polyposis coli (APC) gene, whose product is

83 imiting mutations in human CRC occurs in the adenomatous polyposis coli (APC) gene.

84 omas had somatic truncation mutations to the adenomatous polyposis coli (Apc) gene.

85 nt in mice with heterozygous mutation in the adenomatous polyposis coli (APC) gene.

86 ontinues to be dominated by mutations in the adenomatous polyposis coli (APC) gene.

87 estinal neoplasia caused by mutations of the adenomatous polyposis coli (Apc) gene.

88 s typically associated with mutations in the adenomatous polyposis coli (APC) gene.

89 velop through loss of normal function of the Adenomatous polyposis coli (APC) gene.

90 g, in particular, tumor suppressors TP53 and adenomatous polyposis coli (APC) gene.

91 e generated mice lacking the beta-catenin or adenomatous polyposis coli (Apc) genes in osteoblasts.

92 here that the mouse tumor suppressor protein adenomatous polyposis coli (APC) has a role in AChR clus

93 The adenomatous polyposis coli (APC) I1307K allele is found

94 Wnt/beta-catenin pathway signaling following adenomatous polyposis coli (APC) inactivation.

95 Mutations in the tumor suppressor adenomatous polyposis coli (APC) initiate most colon can

96 The tumor suppressor adenomatous polyposis coli (APC) is a crucial regulator

97 ncluding the brain, and the tumor suppressor adenomatous polyposis coli (APC) is a key negative regul

98 Adenomatous polyposis coli (APC) is a large multidomain

99 Adenomatous polyposis coli (APC) is a microtubule plus-e

100 Adenomatous polyposis coli (APC) is a multifunctional tu

101 The tumor suppressor Adenomatous polyposis coli (APC) is a negative regulator

102 Mutational inactivation of adenomatous polyposis coli (APC) is an early event in co

103 The tumor suppressor adenomatous polyposis coli (APC) is an essential negativ

104 The tumor suppressor adenomatous polyposis coli (APC) is an essential negativ

105 ASE of adenomatous polyposis coli (APC) is associated with path

106 Adenomatous polyposis coli (APC) is best known for its c

107 Mutation of the tumor suppressor adenomatous polyposis coli (APC) is considered an initia

108 The tumor suppressor adenomatous polyposis coli (APC) is implicated in regula

109 The tumor suppressor protein adenomatous polyposis coli (APC) is multifunctional - it

110 Adenomatous polyposis coli (APC) is mutated in colon can

111 Adenomatous polyposis coli (APC) is one such MAP with a

112 Loss of tumor suppressor adenomatous polyposis coli (APC) is thought to initiate

113 aling following loss of the tumor suppressor adenomatous polyposis coli (APC) is thought to initiate

114 ore, the loss of heterozygosity rates at the adenomatous polyposis coli (Apc) locus are unaffected by

115 Today, the tumor suppressor adenomatous polyposis coli (APC) may have the same compl

116 Here, we show that adenomatous polyposis coli (APC) modulates microtubule (

117 vessels in RIP-Tag2 transgenic mouse tumors, adenomatous polyposis coli (apc) mouse adenomas, and imp

118 We report that adenomatous polyposis coli (APC) mutant zebrafish harbor

119 esis that initiation of colorectal cancer by adenomatous polyposis coli (APC) mutation is mediated by

120 Adenomatous polyposis coli (APC) mutation is the most co

121 tween up-regulation of VEGF-A expression and adenomatous polyposis coli (APC) mutational status (acti

122 Adenomatous polyposis coli (APC) mutations are linked to

123 In this study, we show that adenomatous polyposis coli (APC) mutations found in huma

124 nt/beta-catenin pathway activation caused by adenomatous polyposis coli (APC) mutations occurs in app

125 Individuals with heterozygous germline adenomatous polyposis coli (APC) mutations or familial a

126 The tumor suppressor Adenomatous polyposis coli (APC) negatively regulates Wn

127 (CRCs), an initiating mutation occurs in the adenomatous polyposis coli (APC) or beta-catenin gene, a

128 n that have been associated with loss of the adenomatous polyposis coli (APC) or constitutive activat

129 d glycogen synthase kinase 3beta (GSK-3beta)/adenomatous polyposis coli (APC) pathways.

130 Adenomatous polyposis coli (APC) plays a critical role i

131 The tumor suppressor adenomatous polyposis coli (APC) plays a critical role i

132 The tumor suppressor Adenomatous polyposis coli (APC) plays a key role in reg

133 nestin expressing NeuN positive neurons and adenomatous polyposis coli (APC) positive mature oligode

134 in of E-cadherin or a functional fragment of adenomatous polyposis coli (APC) protein (APC-25) comple

135 In interphase cells, the adenomatous polyposis coli (APC) protein accumulates on

136 In vitro data show that the adenomatous polyposis coli (APC) protein associates with

137 ibition of GSK-3beta and accumulation of the adenomatous polyposis coli (APC) protein at the plus end

138 ere, we report that the expression status of adenomatous polyposis coli (APC) protein determines the

139 The adenomatous polyposis coli (APC) protein functions as a

140 The role of wild-type adenomatous polyposis coli (APC) protein in native epith

141 Loss of the adenomatous polyposis coli (APC) protein is a common ini

142 Adenomatous polyposis coli (APC) protein is a large tumo

143 The adenomatous polyposis coli (APC) protein is inactivated

144 rating cells, and induces the interaction of adenomatous polyposis coli (Apc) protein with the plus e

145 CtBP interacts with adenomatous polyposis coli (APC) protein, and is stabili

146 Fap1 also interacts with the adenomatous polyposis coli (Apc) protein, but the functi

147 des the kinases, beta-catenin, axin, and the Adenomatous Polyposis Coli (APC) protein.

148 inked to deficiencies in mismatch repair and adenomatous polyposis coli (APC) proteins, diet, inflamm

149 ing a knockout allele in the gatekeeper gene Adenomatous polyposis coli (Apc) recapitulates familial

150 The tumor suppressor protein adenomatous polyposis coli (APC) regulates cell protrusi

151 Adenomatous polyposis coli (APC) regulates the activity

152 is functionally important for cell migration.Adenomatous polyposis coli (APC) regulates the localizat

153 gene targeting in mice, we demonstrate that adenomatous polyposis coli (APC) serves an essential fun

154 The tumor suppressor protein adenomatous polyposis coli (APC) stabilizes microtubules

155 ne such pathway the tumor-suppressor protein adenomatous polyposis coli (APC) targets RNAs to cell pr

156 Here, we have defined a repeat sequence in adenomatous polyposis coli (APC) that binds to EB1's COO

157 ting factor-responsive cells were defined by adenomatous polyposis coli (APC) time-of-flight mass cyt

158 Binding of adenomatous polyposis coli (APC) to the microtubule plus

159 In turn, KIF17 participates in localizing adenomatous polyposis coli (APC) to the plus ends of a s

160 The adenomatous polyposis coli (APC) tumor suppressor forms

161 Acquired or inherited mutations in the adenomatous polyposis coli (APC) tumor suppressor gene a

162 The adenomatous polyposis coli (APC) tumor suppressor gene e

163 Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene i

164 The Adenomatous Polyposis Coli (APC) tumor suppressor gene i

165 Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene s

166 found in patients harboring mutations in the adenomatous polyposis coli (APC) tumor suppressor gene.

167 The Adenomatous Polyposis Coli (APC) tumor suppressor is a m

168 The adenomatous polyposis coli (APC) tumor suppressor is a m

169 Inactivation of the adenomatous polyposis coli (APC) tumor suppressor is fre

170 The adenomatous polyposis coli (APC) tumor suppressor is ina

171 The adenomatous polyposis coli (Apc) tumor suppressor is inv

172 ce with IEC-specific allelic deletion of the adenomatous polyposis coli (Apc) tumor suppressor locus,

173 atase 2A (PP2A) and must be protected by the adenomatous polyposis coli (APC) tumor suppressor protei

174 Mutation of the adenomatous polyposis coli (APC) tumor suppressor stabil

175 rcinomas contain truncating mutations in the adenomatous polyposis coli (APC) tumor suppressor, a neg

176 in signaling is negatively controlled by the adenomatous polyposis coli (APC) tumor suppressor, which

177 lators of nucleocytoplasmic shuttling of the adenomatous polyposis coli (APC) tumor suppressor.

178 calculating the in vivo mutation rate of the adenomatous polyposis coli (APC) tumor-suppressor gene i

179 ollows a genetic pathway whereby loss of the adenomatous polyposis coli (APC) tumour suppressor and a

180 RNAs in the granules associate with the adenomatous polyposis coli (APC) tumour suppressor and t

181 Mutations in the adenomatous polyposis coli (APC) tumour suppressor are t

182 Mutations in Adenomatous polyposis coli (APC) underlie familial adeno

183 Mutations in adenomatous polyposis coli (APC) underlie the earliest s

184 In this study, the tumor suppressor protein adenomatous polyposis coli (APC) was found to be importa

185 We found that the tumor suppressor adenomatous polyposis coli (APC) was required for microt

186 These mice were crossed with adenomatous polyposis coli (Apc)(min/+) mice, or given a

187 ne the genetic relationship between MPC1 and Adenomatous polyposis coli (APC), a key tumor suppressor

188 Inactivating mutations within adenomatous polyposis coli (APC), a negative regulator o

189 approaches suggest that the tumor suppressor adenomatous polyposis coli (APC), a regulator of Wnt sig

190 Adenomatous polyposis coli (APC), a tumor suppressor com

191 Adenomatous polyposis coli (Apc), a tumor suppressor gen

192 Adenomatous polyposis coli (APC), a tumor suppressor gen

193 Specific site of CpG islands of adenomatous polyposis coli (APC), a well studied tumor s

194 The tumor suppressor adenomatous polyposis coli (APC), an essential negative

195 atenin destruction complex components Axin1, adenomatous polyposis coli (APC), and GSK3beta were also

196 gradation complex in vitro, including Dvl-1, adenomatous polyposis coli (APC), axin, and beta-catenin

197 ein complex containing the proteins axin and adenomatous polyposis coli (APC), both of which bind dir

198 forms a complex with axin (axis inhibitor), adenomatous polyposis coli (APC), casein kinase 1alpha (

199 Rac1-specific exchange factor stimulated by adenomatous polyposis coli (APC), contributing to colore

200 Together with its direct binding partner adenomatous polyposis coli (APC), EB1 can stabilize micr

201 Mutations in known driver genes [e.g., adenomatous polyposis coli (APC), KRAS, or PIK3CA] found

202 Individual crypt adenomatous polyposis coli (APC), p53, K-RAS, and 17p lo

203 in acromegaly patients induced colon p53 and adenomatous polyposis coli (APC), reversing progrowth GH

204 e designed against beta-catenin (Ctnnb1) and adenomatous polyposis coli (Apc), two commonly mutated g

205 ical Wnt signaling by targeting the gene for Adenomatous Polyposis Coli (Apc), which controls Wnt sig

206 e, we show that the tumor suppressor protein adenomatous polyposis coli (APC), which is a known MT-as

207 its expression and activity using models of adenomatous polyposis coli (APC)- and chemotherapy-induc

208 Two adenomatous polyposis coli (APC)-dependent proteasomal d

209 Free beta-catenin is eliminated by two adenomatous polyposis coli (APC)-dependent proteasomal d

210 eracts with beta-catenin through a conserved adenomatous polyposis coli (APC)-like domain.

211 Expression of eIF6 in adenomatous polyposis coli (APC)-mutant colon cancer cel

212 o develop colitis-associated and spontaneous adenomatous polyposis coli (APC)-related tumors of the i

213 P), Skp1, transducin beta-like 1 (TBL1), and adenomatous polyposis coli (APC).

214 runcating mutations in the tumor suppressor, adenomatous polyposis coli (APC).

215 n of a microtubule plus end binding protein, adenomatous polyposis coli (APC).

216 LF4 is a target gene of the tumor suppressor adenomatous polyposis coli (APC).

217 h CIN+ tumor cells correlated with status of adenomatous polyposis coli (APC).

218 glycogen synthase kinase-3beta, axin-1, and adenomatous polyposis coli (APC).

219 to the inactivation of the tumor suppressor adenomatous polyposis coli (APC).

220 by aberrant function of the tumor suppressor Adenomatous polyposis coli (Apc).

221 Loss of function of the adenomatous polyposis coli (APC)/Apc tumor suppressor ge

222 ation suppresses beta-catenin activity in an adenomatous polyposis coli (APC)/glycogen synthase kinas

223 s; and suppresses colonic polyp formation in adenomatous polyposis coli (APC)min/+ mice.

224 We analyzed adenomatous polyposis coli (Apc)min/+/Sigirr-/- mice for

225 vilVEGF1 mice were bred to Min mice (adenomatous polyposis coli [APC] +/-).

226 I, IGF2; tumor suppressor candidate 33, N33; adenomatous polyposis coli, APC; mut-L homolog 1, MLH1;

227 Arm is targeted for proteolysis by the Axin/Adenomatous polyposis coli (Apc1 and Apc2)/Zeste-white 3

228 a-catenin pathway mutations, such as loss of adenomatous polyposis coli, are insensitive to this nove

229 atenin and the destruction complex component adenomatous polyposis coli at a similar SLS motif to the

230 e glycogen synthase kinase 3beta (GSK3beta)- adenomatous polyposis coli-axin-mediated degradation pat

231 Because mutations in adenomatous polyposis coli, beta-catenin and other compo

232 kers associated with colon cancer, including adenomatous polyposis coli, beta-catenin, p53, c-myc, cy

233 coded by the CCND1 gene and activated by the adenomatous polyposis coli-beta-catenin-T-cell factor/ly

234 intestinal tumors driven by mutations in the adenomatous polyposis coli/beta-catenin pathway and acti

235 f cell lines even harboring mutations in the adenomatous polyposis coli/beta-catenin pathway.

236 ble in cell lines harboring mutations in the adenomatous polyposis coli/beta-catenin pathway.

237 erived WNT2 activated canonical signaling in adenomatous polyposis coli/beta-catenin wild-type colon

238 V integration site family (WNT)/beta-catenin/adenomatous polyposis coli (CTNNB1/APC) pathway has been

239 In the context of APC (adenomatous polyposis coli) deficiency (Apc(Min/+) mice)

240 otubule organization and capture dynamics in adenomatous polyposis coli-deficient radial progenitors.

241 in cancer cells by restoration of wild type adenomatous polyposis coli function or expression of a d

242 e intestinal neoplasia (Min) mutation of the adenomatous polyposis coli gene (Apc) and homozygous for

243 adic colon adenomas acquire mutations in the adenomatous polyposis coli gene (APC) and show defects i

244 By using mice with germline mutations in the adenomatous polyposis coli gene (Apc) and/or DNA mismatc

245 Inactivating mutations of the adenomatous polyposis coli gene (APC) or activating muta

246 t human colorectal cancers, mutations in the adenomatous polyposis coli gene (APC) or CTNNB1 constitu

247 as associated with reduced expression of the adenomatous polyposis coli gene (APC).

248 iation domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in his

249 Mice carrying and non-sense mutation in Adenomatous polyposis coli gene at site R850, which desi

250 erpreted to represent the homozygous loss of adenomatous polyposis coli gene function.

251 olyposis because of germline mutation of the adenomatous polyposis coli gene is characterized by deve

252 sis kindreds harboring an identical germline adenomatous polyposis coli gene mutation.

253 its other negative regulators, such as axin, adenomatous polyposis coli gene product (APC), and glyco

254 eta-catenin by inhibiting its binding to the adenomatous polyposis coli gene product and subsequent g

255 in, where carrier proteins like axin and the adenomatous polyposis coli gene product APC interact wit

256 comparatively rare missense variants in the adenomatous polyposis coli gene, which is responsible fo

257 eficient mice carrying the Min allele of the adenomatous polyposis coli gene.

258 and compared to control mice carry wildtype Adenomatous polyposis coli gene.

259 t is caused by inactivating mutations in the Adenomatous polyposis coli gene.

260 g in T cell lineages by deletion of the Apc (adenomatous polyposis coli) gene causes spontaneous T ce

261 and function through Disheveled (Dvl), Axin, adenomatous polyposis coli, glycogen synthase kinase 3be

262 -catenin pathway regulatory genes, including adenomatous polyposis coli, GSK3beta, axin 1, beta-caten

263 nction of the tumor suppressor protein, APC (adenomatous polyposis coli), in the regulation of base e

264 mutation of the Wnt repressor APC (encoding adenomatous polyposis coli) leads to a state of aberrant

265 that contained mutations in either the APC (adenomatous polyposis coli) locus or in an allele of bet

266 ted signaling and glycogen synthase kinase-3/adenomatous polyposis coli-mediated beta-catenin activat

267 ence in normal intestinal homeostasis and in adenomatous polyposis coli-mediated tumorigenesis.

268 Crossing Tfam(+/-) mice to the adenomatous polyposis coli multiple intestinal neoplasia

269 Here, we demonstrate that adenomatous polyposis coli mutant APC(Min/+) mice, which

270 Inherited and somatic mutations in the adenomatous polyposis coli occur in most colon cancers,

271 RC) harboring functional mutations in either adenomatous polyposis coli or beta-catenin.

272 ling induced by loss of the tumor suppressor adenomatous polyposis coli or casein kinase 1alpha uncov

273 Additional examination of one or more of the adenomatous polyposis coli, p14ARF, p16INK4a, or death a

274 Most information about the roles of the adenomatous polyposis coli protein (APC) and its binding

275 at RNAi-mediated depletion of two kMAPs, the adenomatous polyposis coli protein (APC) and its binding

276 olding protein Axin and the tumor suppressor adenomatous polyposis coli protein (APC) are critical co

277 We recently identified adenomatous polyposis coli protein (APC) as a key regula

278 Here we report that the tumour suppressor adenomatous polyposis coli protein (APC) directs the loc

279 We propose that adenomatous polyposis coli protein (APC) is a key coordi

280 d beta-catenin requires interaction with the adenomatous polyposis coli protein but not with TCF for

281 ixed disulfides with both beta4-spectrin and adenomatous polyposis coli protein in the cytosol.

282 n from Mlp of a region similar to one in the adenomatous polyposis coli protein involved in EB1 bindi

283 ows that the actin-nucleating ability of the adenomatous polyposis coli protein is required for disas

284 DLD-1 colon carcinoma cells with the mutated adenomatous polyposis coli protein.

285 We had shown that the APC (adenomatous polyposis coli) protein controls localizatio

286 versely, RNAi of the beta-catenin antagonist adenomatous polyposis coli results in the regeneration o

287 However, little is known about adenomatous polyposis coli's (APC's) role in the mammali

288 W480 cells stably transformed with wild-type adenomatous polyposis coli showed decreased beta-catenin

289 on, and beta-catenin, a component of the Wnt-adenomatous polyposis coli signaling pathway, contribute

290 cognized a different autoantigen, except for adenomatous polyposis coli that was recognized by sera o

291 ectly targets the tumor suppressor gene APC (adenomatous polyposis coli), thereby affecting Wnt (Wing

292 Germ line mutations in the Adenomatous polyposis coli tumor suppressor gene cause a

293 syndrome caused by germline mutations in the adenomatous polyposis coli tumor suppressor gene.

294 he microtubule motor cytoplasmic dynein, the adenomatous polyposis coli tumor suppressor protein (APC

295 centrosome function and cortically localized Adenomatous Polyposis Coli tumor suppressor protein to o

296 Mutations in the APC (adenomatous polyposis coli) tumor suppressor gene cause

297 The APC gene encodes the adenomatous polyposis coli tumour suppressor protein, ge

298 All patients were tested for the adenomatous polyposis coli variants I1307K and E1317Q, a

299 Inactivation of the tumor suppressor adenomatous polyposis coli, with the resultant activatio

300 Disruption of Apc (adenomatous polyposis coli) within hepatocytes activates